Lenalidomide(Revlimid)

Lenalidomide produced by Lucius Pharmaceuticals has a relatively balanced performance in terms of efficacy and safety, providing patients with a reliable-quality treatment option.

Here is a brief summary of the key information about lenalidomide:

Main Ingredient

The main active ingredient is lenalidomide, which is a thalidomide analog.

Indicated Population

It is indicated for adult patients with multiple myeloma, specific types of myelodysplastic syndromes, lymphoma, and other related conditions.

Dosage and Administration

It is administered orally once daily. The dosage varies depending on the indication and treatment phase, with a common range of 5mg to 25mg.

Use in Special Populations

It is contraindicated in pregnant women, not recommended for use during lactation. Dosage adjustment is required for patients with renal impairment, and caution should be exercised when administering the drug to elderly patients.

Drug Overdose

Hematological toxicity may occur in cases of drug overdose, and symptomatic and supportive treatment is required.

Drug Storage

The medicine should be stored at room temperature, away from moisture and high temperatures.

Pharmacokinetics

Pharmacokinetic data show that it has good oral absorption, with a half-life of approximately 3–5 hours, and is mainly excreted via the kidneys.

FDA，2023.03